title: Cytomegalovirus infection in children with blood diseases.
abstract: The study included 68 children aged from 1 to 16 years treated for acute leukemias and bone marrow aplasia. Cytomegalovirus antigen (CMV) was detected by immunofluorescence in urinary sediment cells and in cell cultures after their inoculation with CMV. Besides, the activity of IgG and IgM classes of antibodies against CMV was determined. Presence of one or more markers of CMV infection was demonstrated in 31 children, i.e., 45.5%. In eight children (11.7%) clinical manifestation of CMV infection were demonstrable with fever, hepatitis, pneumonia, rash. In all the children who completed the treatment with hyperimmune globulin, regression of clinical symptoms and signs of CMV infection with the elimination of virus antigen from urine was achieved.
authors.affiliation: Department of Pediatric Hematology/Oncology, Medical Academy, Warsaw.
authors.forename: R
authors.initials: R
authors.lastname: Rokicka-Milewska
authors.forename: J
authors.initials: J
authors.lastname: Pacholska
authors.forename: K
authors.initials: K
authors.lastname: Lukowska
authors.forename: W
authors.initials: W
authors.lastname: Paciorkiewicz
authors.forename: M
authors.initials: M
authors.lastname: Jastrzebska
mesh_terms: D000293:Adolescent; D000741:Anemia, Aplastic / Q000150:complications / Q000276:immunology / Q000628:therapy*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D001215:Asparaginase / Q000008:administration & dosage; D002648:Child; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D003586:Cytomegalovirus Infections / Q000209:etiology / Q000276:immunology / Q000628:therapy*; D003630:Daunorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007108:Immune Tolerance / Q000187:drug effects / Q000276:immunology; D007116:Immunization, Passive; D007223:Infant; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D015470:Leukemia, Myeloid, Acute / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D009894:Opportunistic Infections / Q000209:etiology / Q000276:immunology / Q000628:therapy*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D011241:Prednisone / Q000008:administration & dosage; D013866:Thioguanine / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage; D005719:gamma-Globulins / Q000008:administration & dosage*
chemical_list: D005719:gamma-Globulins; D003561:Cytarabine; D014750:Vincristine; D003520:Cyclophosphamide; D001215:Asparaginase; D013866:Thioguanine; D011241:Prednisone; D008727:Methotrexate; D003630:Daunorubicin